Trial Parameters
Condition ANCA Associated Vasculitis
Sponsor Xiangya Hospital of Central South University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 500
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2022-03-16
Completion 2027-03-16
Interventions
No Intervention
Brief Summary
This study aimed to explore the incidence of Anti-neutrophil cytoplasmic antibody (ANCA）-associated vasculitis (AAV) progression and its association with adverse consequences. It will enroll approximately 500 AAV patients in Hunan province of China and follow-up for at least 5 years. Demographic characteristics, clinical and laboratory data will be collected at baseline and every follow-up. The principal clinical outcomes of the study consist of end stage renal disease (ESRD) and death.
Eligibility Criteria
Inclusion Criteria: * Fulfill 2012 criteria of ANCA associated vasculitis and agree to sign informed consent Exclusion Criteria: * Do not agree to sign informed consent